Literature DB >> 233147

The nucleic acid and proteins of epizootic haemorrhagic disease virus.

H Huismans, C W Bremer, T L Barber.   

Abstract

Purified epizootic haemorrhagic disease virus (EHDV) was shown to contain 10 double-stranded RNA segments and a double-layered protein capsid with 4 major and 4 minor polypeptides. The virus differed from bluetongue virus (BTV), the orbivirus prototype, in that EHDV had an additional minor polypeptide component. This component, together with the major polypeptides P2 and P5, formed the outer capsid layer of the virus. The extra polypeptide apparently stabilizes this layer since, unlike BTV, EHDV was quite stable on CsCl gradients at both pH 7,0 and 8,0. EHD virions were found to have a density of 1,36 g/microliter, while particles without the outer capsid layer were isolated and had a density of 1,40 g/microliter. Two non-capsid polypeptides, P5A and P6A, were identified in addition to the 8 capsid polypeptides. Polypeptide P5A was synthesized in excess of all the others. There was little homology between the nucleic acids of EHDV and BTV with only 5-10% cross-hybridization. No hybrid double-stranded RNA segments were identified. We found by cross-immune precipitation that the major core polypeptides of the 2 viruses (P7 and P3) have common antigenic determinants.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 233147

Source DB:  PubMed          Journal:  Onderstepoort J Vet Res        ISSN: 0030-2465            Impact factor:   1.792


  18 in total

1.  Tissue tropism and target cells of bluetongue virus in the chicken embryo.

Authors:  L Wang; M C Kemp; P Roy; E W Collisson
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

2.  VP2 is the major exposed protein on orbiviruses.

Authors:  S A Lewis; M J Grubman
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

3.  A comparison of different cloned genome segments of epizootic haemorrhagic disease virus as serogroup-specific probes.

Authors:  L H Nel; H Huismans
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

Review 4.  The biochemistry of orbiviruses. Brief review.

Authors:  R P Spence; N F Moore; P A Nuttall
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

5.  PCR detection of North American and Central African isolates of epizootic hemorrhagic disease virus (EHDV) based on genome segment 10 of EHDV serotype 1.

Authors:  I E Aradaib; W C Wilson; C E Schore; M E Mohammed; T D Yilma; J S Cullor; B I Osburn
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

6.  The evolution of two homologues of the core protein VP6 of epizootic haemorrhagic disease virus (EHDV), which correspond to the geographical origin of the virus.

Authors:  S J Anthony; K E Darpel; S Maan; G Sutton; H Attoui; P P C Mertens
Journal:  Virus Genes       Date:  2009-10-15       Impact factor: 2.332

7.  RT-PCR assays for seven serotypes of epizootic haemorrhagic disease virus & their use to type strains from the Mediterranean region and North America.

Authors:  Narender S Maan; Sushila Maan; Kyriaki Nomikou; Donna J Johnson; Mehdi El Harrak; Hafsa Madani; Hagai Yadin; Serife Incoglu; Kadir Yesilbag; Andrew B Allison; David E Stallknecht; Carrie Batten; Simon J Anthony; Peter P C Mertens
Journal:  PLoS One       Date:  2010-09-17       Impact factor: 3.240

8.  Simple procedure for preparation of bluetongue virus and epizootic hemorrhagic disease virus antigens for agar gel immunodiffusion.

Authors:  J L Stott; B I Osburn
Journal:  J Clin Microbiol       Date:  1983-12       Impact factor: 5.948

9.  Vaccinia virus expression of the VP7 protein of South African bluetongue virus serotype 4 and its use as an antigen in a capture ELISA.

Authors:  M Cloete; D H du Plessis; A A van Dijk; H Huismans; G J Viljoen
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

10.  Development of polymerase chain reaction for specific identification of epizootic hemorrhagic disease virus serotype 1.

Authors:  I E Aradaib; J W McBride; W C Wilson; B I Osburn
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.